A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
Active, not recruiting · Phase 1, Phase 2 · NCT05092347
Conditions: Chronic Kidney Disease (CKD)
At a glance
- Research payments reported, 2025
- $698,447
- U.S. investigators named
- 9
- Sites paid
- 10
- Planned or actual enrollment
- 43
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Vonsetamig (drug)
- Dates
- Started 2022-08-02; completion 2027-11-22
- Results posted
- Not yet
The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation. Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA. The study is looking at several other research questions, including: * Side effects that may be experienced from taking vonsetamig * How vonsetamig works in the body * How much vonsetamig is present in the blood * If vonsetamig works to lower levels of antibodies to HLA
From ClinicalTrials.gov, last updated 2026-06-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $698,447 in research payments for this study in 2025 (326 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Stanley Jordan, MD Nephrology (Kidney) · West Hollywood, CA
- Robert R. Redfield, MD Transplant Surgery · Orange, CA
- Flavio G. Vincenti, M.D. Internal Medicine · San Francisco, CA
- Abhishek Kumar, M.D. Nephrology (Kidney) · New Haven, CT
- John Friedewald, MD Nephrology (Kidney) · Chicago, IL
- Divyanshu Malhotra, MD Nephrology (Kidney) · Baltimore, MD
- Raja Kandaswamy, MD General Surgery · Minneapolis, MN
- Nicole M. Ali, MD Nephrology (Kidney) · New York, NY
- Ronald F. Parsons, MD Cardiothoracic Surgery · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $279,685
- Ronald Reagan UCLA Medical Center, CA $162,250
- Hospital of Univ of Pennsylvania, PA $71,664
- Regents of the University of Minnesota $44,783
- Uci Health - Fountain Valley, CA $39,589
- Cedars-Sinai Medical Center, CA $30,601
- Johns Hopkins University $29,505
- New York University $15,466
- Yale University $12,559
- Northwestern University $12,346
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.